Information Provided By: 
Fly News Breaks for January 23, 2019
GRFS, RIGL
Jan 23, 2019 | 11:15 EDT
H.C. Wainwright analyst Joseph Pantginis raised his price target for Rigel Pharmaceuticals to $8 from $7.50 saying the company checked an "important box" by signing a partnership for Europe with Grifols (GRFS). The analyst is "pleased" with the Grifols partnership and the terms, "especially the royalty." He's confident Rigel is working on different fronts to boost fostamatinib's clinical and commercial potential outside the U.S. and reiterates a Buy rating on the shares.
News For RIGL;GRFS From the Last 2 Days
There are no results for your query RIGL;GRFS
